Press Room
Portland-area researchers harness immune system to shrink tumors
12/09/2013
Portland-area researchers have scored promising results in the hottest field in cancer research today: Using the immune system to fight tumors.
Child with kidney cancer loses health insurance under Obamacare
12/08/2013
A boy with a rare type of cancer who had his health insurance plan canceled after the Affordable Care Act took effect...
Cystic partially regressed clear cell renal cell carcinoma
12/07/2013
A potential mimic of multilocular cystic renal cell carcinoma
Predicting outcome for high-dose IL-2 therapy in cancer patients
12/03/2013
One of the most potent forms of immunotherapy for patients with metastatic melanoma and renal cell carcinoma is high-dose (HD) bolus IL-2 therapy. Approximately 15% of patients respond to HD IL-2 therapy, with almost 5% going into complete remission; however, use of HD IL-2 therapy is limited due to the toxic effects associated with treatment. Because HD IL-2-associated toxicity is severe, it would be beneficial for clinicians to determine if a patient would respond favorably to this treatment prior to side effect onset.
Prognostic factors of patients with metastatic renal cell carcinoma with removed metastases
11/29/2013
OBJECTIVE: To investigate the prognosis and prognostic factors of patients with metastatic renal cell carcinoma who underwent metastasectomy.
News Feed| NeonCRM by Neon One |